Source-grounded facts extracted from Denali Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Denali Therapeutics Inc. entered into PRV Transfer Agreement valued at $195 million (effective 2026-06-12).
“On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”).”
Denali Therapeutics Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-03 meeting.
“Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”
Denali Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-03 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Denali Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.
“Election of three Class III directors to hold office until the 2029 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 7, 2026, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Denali Therapeutics Inc. terminated Collaboration Agreement with Takeda Pharmaceutical Company Limited (effective 2018-01-03).
“On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).”
Denali Therapeutics Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC as representatives of the several underwriters valued at Public offering of 9,142,857 shares of common stock at $17.50 per share and pre-funded warrants to p (effective 2025-12-09).
“On December 9, 2025, Denali Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the public offering of 9,142,857 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price to the public of $17.50 per share (the “Firm Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,285,714 shares of Common Stock at a price to the public of $17.49 per underlying share. Under the terms of the Underwriting Agreement, the Underwriters have agreed to purchase the Firm Shares from the Company at a price of $16.625 per share and the Pre-Funded Warrants at a price of $16.615 per underlying share. Additionally, the Company has granted the Underwriters an option exercisable for 30 days from the date of the”
Denali Therapeutics Inc. entered into Royalty Agreement with Royalty Pharma plc valued at up to $275 million (effective 2025-12-04).
“On December 4, 2025, Denali Therapeutics Inc. (“Denali” or the “Company”) entered into a synthetic royalty funding agreement (the “Royalty Agreement”) with Royalty Pharma plc (“Royalty Pharma”).”
Denali Therapeutics Inc.: Amended and restated bylaws to update advance notice procedures, conform to universal proxy rules, and align with Delaware law, effective upon approval (effective 2024-11-12).
“On November 12, 2024, the Board of Directors (the “ Board ”) of Denali Therapeutics Inc. (the “ Company ”), acting upon the recommendation of the Board’s Corporate Governance and Nominating Committee, approved and adopted amended and restated bylaws (as so amended and restated, the “ Amended and Restated Bylaws ”), which became effective upon such approval and adoption.”
Denali Therapeutics Inc. reported the first quarter ended March 31, 2024 results: revenue There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended, net income Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter.
“Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter ended March 31, 2023. There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.”
Denali Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.”
Denali Therapeutics Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $500 million (effective 2024-02-27).
“On February 27, 2024, Denali Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 3,244,689 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at $17.07 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 26,046,065 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $17.06 per Pre-Funded Warrant.”
Denali Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 7, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
Denali Therapeutics Inc. amended Amendment with Biogen MA, Inc. and Biogen International GmbH (effective 2023-08-17).
“on August 17, 2023, Denali Therapeutics Inc., (“Denali” or “we”) and Biogen MA, Inc. and Biogen International GmbH, (collectively, “Biogen”) executed an Amendment to the Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement (the “Amendment”).”
Denali Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.
“On August 8, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2023.”
Denali Therapeutics Inc. shareholders approved Advisory Vote to Approve Executive Compensation at the 2023-06-01 meeting.
“Proposal 3 - Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 98,002,580 6,571,884 50,220 8,297,787”
Denali Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 112,694,203 198,540 29,728 —”
Denali Therapeutics Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders. at the 2023-06-01 meeting.
“Proposal 1 - Election of Directors Election of three Class III directors to hold office until the 2026 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal. Nominees For Withheld Broker Non-Votes Jennifer Cook 87,451,911 17,172,773 8,297,787 David Schenkein, M.D. 87,642,096 16,982,588 8,297,787 Ryan J. Watts, Ph.D. 103,702,078 922,606 8,297,787”
Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.
“Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
Denali Therapeutics Inc. reported financial results for the fourth quarter ended December 31, 2022.
“On February 27, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.”
Denali Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $103.3 million.
“Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
Alexander Schuth was appointed as Chief Operating and Financial Officer at Denali Therapeutics Inc..
“Alexander Schuth, M.D., current Chief Operating Officer and Secretary of the Company, will add the Chief Financial Officer role to his current responsibilities, becoming Denali’s Chief Operating and Financial Officer.”
Steve Krognes was appointed as Director at Denali Therapeutics Inc..
“On March 14, 2022, Mr. Krognes was appointed to the Board, effective May 1, 2022.”
Steve Krognes changed role as Chief Financial Officer at Denali Therapeutics Inc..
“Steve Krognes will transition from his role as Chief Financial Officer to join the Company’s Board of Directors as of May 1, 2022”
Erik Harris was appointed as Director at Denali Therapeutics Inc..
“On February 3, 2022, Erik Harris was appointed to the Board of Directors (the “Board”) and to the Audit Committee of the Board (the "Audit Committee") of Denali Therapeutics Inc. (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.